Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials...

por Lipton, Richard B., Charleston, Larry, Tassorelli, Cristina, Brevig, Thomas, Hirman, Joe, Cady, Roger
Publicado 2022

Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine

por Buse, Dawn C., Winner, Paul K., Charleston, Larry, Hirman, Joe, Cady, Roger, Brevig, Thomas
Publicado 2022

Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study

por Charleston, Larry, Talon, Brian, Sullivan, Christine, Anderson, Carlton, Kymes, Steven, Regnier, Stephane A., Soni-Brahmbhatt, Seema, Nahas, Stephanie J.
Publicado 2023

Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review

por Blumenfeld, Andrew M., Lipton, Richard B., Silberstein, Stephen, Tepper, Stewart J., Charleston, Larry, Landy, Stephen, Kuruvilla, Deena E., Manack Adams, Aubrey
Publicado 2023